Company intelligence / Profile preview

Motus Therapeutics, Inc.

Ownership: Private
Development stage: Phase 2

Overview

Motus Therapeutics developed relamorelin, a ghrelin agonist peptide for diabetic gastroparesis. In a randomized, double-blind Phase IIb trial with over 390 patients, relamorelin showed substantial efficacy in reducing symptoms such as nausea and vomiting and improving gastric motility. The drug was generally well-tolerated but had some dose-related adverse events related to glycemic control. High placebo response limited statistical significance on the primary endpoint but overall results were encouraging enough for Allergan to acquire the company and plan Phase III trials.[3][4]

Therapeutic areas: Gastroenterology
Modalities: Peptide therapeutics[2][3]Small molecules (inferred from peptide focus)
Industry: Biotech

Drug pipeline

1 asset

relamorelin

Phase 2

Indications: Diabetic gastroparesis

Partnerships

Rhythm Holding Company LLC was parent prior to Allergan's acquisitionNew Enterprise Associates was an investor partner.[6]

Beyond the preview

Go deeper on Motus Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Motus Therapeutics, Inc..

Explore the full profile